Condition: TP53 Y220C Mutation · Advanced Solid Tumors · Sponsor: PMV Pharmaceuticals, Inc
This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.
This description comes directly from the study's public registry record.
SCRI Medical Support Center · 1-615-329-7286 · SCRI.InnovationsMedical@scri.com
PMV Pharma Clinical Study Information Center · 609-235-4038 · clinicaltrials@pmvpharma.com
Always discuss trial participation with your own doctor first.
| HealthOne Denver | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Orlando, Florida, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| SCRI at Mary Crowley | Dallas, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07372625